文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

遗传变异与舒尼替尼高暴露的关联:全基因组关联研究

Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer.
PubMed 文献 · Br J Clin Pharmacol · 2024-08-06

本研究采用全基因组关联研究设计,纳入69例常规治疗药物监测中剂量归一化舒尼替尼血浆浓度超阈值的病例和345例耐受标准剂量50mg间歇方案的EuroTARGET历史队列对照,检验单核苷酸变异与舒尼替尼高暴露的关联。

要点

  • rs6923761与舒尼替尼高暴露显著相关(P=7.86×10^-19),机制尚待阐明。
  • 既往药代动力学通路候选基因SNV与疗效/毒性的关联未被证实。

核心结论

  • rs6923761(GLP-1受体基因)与舒尼替尼高暴露显著相关,但机制未明,需进一步研究。
  • 未能证实既往候选基因中SNV与舒尼替尼疗效和毒性的关联。

研究设计与样本

  • 全基因组关联研究,病例为常规TDM中剂量归一化舒尼替尼血浆浓度>87.5 ng/mL(间歇给药)或>75 ng/mL(连续给药)的患者。
  • 对照来自EuroTARGET历史队列,为耐受标准剂量50 mg间歇方案的患者。
  • 关联分析纳入69例病例和345例对照,SNV显著性阈值P≤5×10^-8,提示性阈值5×10^-8<P≤5×10^-6。

主要发现

  • rs6923761位于胰高血糖素样肽1受体基因,与舒尼替尼暴露升高显著相关(P=7.86×10^-19)。
  • 既往报道的药代动力学通路候选基因SNV与疗效和毒性的关联未获证实。

关键数值与推荐

  • 间歇给药方案目标总血浆浓度(舒尼替尼及活性代谢物)为50-87.5 ng/mL。
  • 约10-21%患者暴露>87.5 ng/mL,与毒性风险增加相关。
  • 病例定义:间歇给药剂量归一化浓度>87.5 ng/mL或连续给药>75 ng/mL。

临床怎么用

  • 对接受舒尼替尼治疗的患者,可结合TDM识别高暴露者,警惕毒性风险。
  • rs6923761目前尚不能直接用于临床剂量决策,需进一步验证。

局限性

  • rs6923761与高暴露的 underlying 机制尚未阐明。
  • 对照组来自历史队列,可能存在人群与用药方案差异。
  • 样本量有限(69例病例),提示性关联需独立验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Sunitinib exhibits considerable interindividual variability in exposure. While the target total plasma concentration of sunitinib and its active metabolite is 50-87.5 ng/mL for the intermittent dosing schedule, ~10-21% of patients experience higher exposures (>87.5 ng/mL), correlated with an increased risk for toxicity. Previous research identified single nucleotide variants (SNVs) in genes from the sunitinib pharmacokinetic pathway to be associated with efficacy and toxicity. However, significant interindividual variability in exposure remains unexplained. Our aim was to identify genetic variants associated with supratherapeutic exposure of sunitinib. METHODS: This was a genome-wide association study. Cases were identified during routine therapeutic drug monitoring and consisted of patients with dose-normalized sunitinib plasma concentrations >87.5 ng/mL (intermittent dosing) or >75 ng/mL (continuous dosing). Controls were sampled from the historical cohort EuroTARGET who tolerated the standard dose of 50 mg in an intermittent schedule. SNVs were tested for an association with sunitinib exposure. A P-value ≤5 × 10-8 was considered significant and a P-value between 5 × 10-8 and 5 × 10-6 was considered suggestive. RESULTS: Sixty-nine cases and 345 controls were included for association analysis. One SNV (rs6923761), located on the gene glucagon-like peptide 1 receptor, was significantly associated with increased sunitinib exposure (P = 7.86 × 10-19). Twelve SNVs were suggestive for an association with sunitinib exposure (P ≤ 5 × 10-6). CONCLUSIONS: While rs6923761 is associated with high sunitinib exposure, the underlying mechanism is not yet clarified and warrants further investigation. [Corrections made on 23 September 2024, after first online publication: In the preceding sentence, identifier rs6923671 has been changed to rs6923761 in this version.] We could not confirm the earlier found associations between SNVs in candidate genes involved in the pharmacokinetic pathway of sunitinib and its efficacy and toxicity.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Giraud EL, Krens SD, Böhringer S, et al. Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer. Br J Clin Pharmacol. 2024. PMID: 39107874. doi:10.1111/bcp.16196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。